Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts on Near Term Uotrends -- Ignore unavailable to you. Want to Upgrade?

To: Chisy who wrote (229)	2/23/2000 11:14:00 PM
From: Jibacoa	Respond to of 1404

Some results from the scan on Wednesday Feb.23,2000: Sorted by % gain on descending order: ZMAX 188.1% SNTKY 41.8% DDIM 41.75% CTE 40.58% USDL 35.59% IDBE 31.29% BASI 31.25% NMPS 27.07% SES 26.44% IISLF 25.78% QDRMY 25.64% JET 23.21% SCLN 23.20% OSIS 21.74% AGTO 20.71% VSCI 17.82% MFCO 16.57% SFT 15.53% ELGT 15.22% WHT 15.05% MILT 14.97% KFI 13.77% NERX 13.64% OPI 13.12% CMSS 13.04% EIL 12.18% EVMD 11.92% NYMX 10.96% INVI 10.63% MATX 10.32% Some of the other "hot ones" besides ZMAX: EACO 125% CDTS 81.86% CPWY 78.76% REGN 75.45% QDIN 70.59% AVGP 57.14% NXTP 50.63% BIKR 48.18% ECTL 45.45% And from the OTC BB, the "super hots": VSSI 3100% S0LX 900% TURN 316.57% CGRDE 300% SOVI 300% PACE 275% SALX 201.61% CAMB 189.92% Good luck to all. Bernard

To: Chisy who wrote (229)	2/24/2000 12:31:00 AM
From: Jibacoa	Read Replies (1) \| Respond to of 1404

XOMA: As you know, it formed a temporary double-top with the Hs of last Thursday & Friday (12.375 and 12.5 respectively) It has recovered from the down-gap yesterday ( to 8). It needs to close above today's H (10 1/4) before it tries to test last week's Hs. As you also probably know they are developing NEUPREX which is a derivative of human bactericidal/permeability-increasing protein and may have value in fighting bacterial infections. They also have I-PREX which is a topical formulation for ophthalmic disorders, and MYCOPREX which is a fungicidal compound intended for systemic fungal infections. In the last reported Q ended 9/30/99 their revenue fell 29% and the net loss although lower, was still 37.7 million. The insiders, which own only 4% have bought some shares lately (1,000 ). The institutions, which hold 10% have reportedly bought 734,000 shares in last Q. As you know their financial situation is not good. (Book value is $-0.16) and they have a pretty good size float of 53.3 million. They reportedly still had 22.3 million in cash in last Q. In summary, it is a very speculative situation. Their products seem to hold great promise if they can get FDA approval and can bring them to market. The fact that the institutions have been buying lately is a good sign. I would like to see it breaking last week's Hs, which was a new H since 1993. The March 1992 H was 24 1/2. Good luck with it. Bernard